论文部分内容阅读
目的:探讨复方苦参注射液联合肝动脉化疗栓塞术(TACE)治疗原发性肝癌的临床疗效及不良反应。方法:将216例原发性肝癌患者随机分为对照组(单纯应用TACE)和治疗组(复方苦参注射液联合TACE)各108例,评价比较两组患者的近期疗效、治疗前后相关指标水平及不良反应。结果:两组均无CR病例。治疗组总有效率66.7%(72/108),对照组总有效率63.9%(69/108);两组比较差异无统计学意义(P>0.05)。治疗组生活质量及机体的免疫功能改善总有效率高于对照组,差异具有统计学意义(均P<0.05),治疗组在静滴复方苦参注射液过程中,无1例出现不良反应。结论:复方苦参注射液联合TACE治疗中晚期原发性肝癌虽然不能明显增加疗效,但能明显改善生活质量及机体的免疫功能,减轻介入治疗的不良反应。
Objective: To investigate the clinical efficacy and side effects of compound Kushen injection combined with transcatheter arterial chemoembolization (TACE) in the treatment of primary liver cancer. Methods: A total of 216 patients with primary liver cancer were randomly divided into control group (TACE alone) and treatment group (compound Kushen injection combined with TACE) in 108 cases. The curative effect of the two groups were compared and evaluated before and after treatment And adverse reactions. Results: There were no CR cases in both groups. The total effective rate was 66.7% (72/108) in the treatment group and 63.9% (69/108) in the control group. There was no significant difference between the two groups (P> 0.05). The total effective rate of the treatment group and the improvement of the immune function were higher than those of the control group (all P <0.05). No adverse reactions occurred in the treatment group during the intravenous injection of Compound Kushen Injection. Conclusion: Compound Kushen injection combined with TACE in the treatment of advanced primary hepatocellular carcinoma can not obviously increase the curative effect, but it can obviously improve the quality of life and the immune function of the body and relieve the adverse reactions of interventional therapy.